Pyruvate dehydrogenase complex component E2-specific T-cell receptor (PDC-E2-specific TCR)

The Pyruvate dehydrogenase complex component E2-specific T-cell receptor (PDC-E2-specific TCR) is a specialized immune receptor found on CD4+ and CD8+ T lymphocytes that plays a central role in the pathogenesis of Primary Biliary Cholangitis (PBC) (Gershwin et al., 2005, PMID: 15633132). PDC-E2, or dihydrolipoyl transacetylase, is the immunodominant autoantigen in PBC, and these specific TCRs recognize its epitopes when presented by Major Histocompatibility Complex (MHC) molecules on biliary epithelial cells (Shimoda et al., 1998, PMID: 9462486). Upon binding, these T cells initiate an autoimmune attack characterized by the production of pro-inflammatory cytokines and direct cytotoxic destruction of the small intrahepatic bile ducts (Kita et al., 2002, PMID: 12117477). This localized immune response leads to chronic cholestasis and progressive liver fibrosis. In therapeutic contexts, these TCRs are considered targets for precision immunotherapy aimed at depleting or silencing the specific autoreactive T-cell clones responsible for liver damage. While standard treatments like Ursodeoxycholic acid focus on bile acid management, experimental therapies such as CNP-104 are designed to induce immune tolerance specifically toward PDC-E2-reactive T cells (Cour Pharmaceuticals, 2024). Other approaches include the use of calcineurin inhibitors like Cyclosporine to dampen TCR-mediated signaling. Monitoring the frequency of these specific TCRs and the presence of anti-mitochondrial antibodies (AMA) serves as a vital biomarker for patient selection and monitoring therapeutic efficacy (Lleo et al., 2014, PMID: 24530605).

Other names

Anti-PDC-E2 T-cell receptorDihydrolipoyl transacetylase-specific T-cell receptorPDC-E2-reactive T-cell receptorPDC-E2-specific TCR

Recognition of PDC-E2 peptide-MHC complexes leading to T-cell activation and biliary destruction; therapeutic modulation aims to inhibit this signaling or induce immune tolerance.